Page last updated: 2024-10-31

metoprolol and Muscular Dystrophy, Duchenne

metoprolol has been researched along with Muscular Dystrophy, Duchenne in 4 studies

Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.
metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.

Muscular Dystrophy, Duchenne: An X-linked recessive muscle disease caused by an inability to synthesize DYSTROPHIN, which is involved with maintaining the integrity of the sarcolemma. Muscle fibers undergo a process that features degeneration and regeneration. Clinical manifestations include proximal weakness in the first few years of life, pseudohypertrophy, cardiomyopathy (see MYOCARDIAL DISEASES), and an increased incidence of impaired mentation. Becker muscular dystrophy is a closely related condition featuring a later onset of disease (usually adolescence) and a slowly progressive course. (Adams et al., Principles of Neurology, 6th ed, p1415)

Research Excerpts

ExcerptRelevanceReference
" Secondary: changes of a) LV-FS from baseline, b) blood pressure, c), heart rate and autonomic function in ECG and Holter-ECG, e) cardiac biomarkers and neurohumeral serum parameters, f) quality of life, and g) adverse events."6.90Effect and safety of treatment with ACE-inhibitor Enalapril and β-blocker metoprolol on the onset of left ventricular dysfunction in Duchenne muscular dystrophy - a randomized, double-blind, placebo-controlled trial. ( Dittrich, S; Ebinger, F; Graf, E; Heilmann, A; Khalil, M; Kirschner, J; Korenke, C; Lange, M; Motz, R; Müller-Felber, W; Neudorf, U; Pattathu, J; Pozza, RD; Schara, U; Schröder, R; Stiller, B; Trollmann, R; von Au, K; von der Hagen, M; Weiss, K; Wiechmann, N; Wilichowski, E, 2019)
" Secondary: changes of a) LV-FS from baseline, b) blood pressure, c), heart rate and autonomic function in ECG and Holter-ECG, e) cardiac biomarkers and neurohumeral serum parameters, f) quality of life, and g) adverse events."2.90Effect and safety of treatment with ACE-inhibitor Enalapril and β-blocker metoprolol on the onset of left ventricular dysfunction in Duchenne muscular dystrophy - a randomized, double-blind, placebo-controlled trial. ( Dittrich, S; Ebinger, F; Graf, E; Heilmann, A; Khalil, M; Kirschner, J; Korenke, C; Lange, M; Motz, R; Müller-Felber, W; Neudorf, U; Pattathu, J; Pozza, RD; Schara, U; Schröder, R; Stiller, B; Trollmann, R; von Au, K; von der Hagen, M; Weiss, K; Wiechmann, N; Wilichowski, E, 2019)
"Most patients with Duchenne muscular dystrophy (DMD) will develop cardiomyopathy; however, the evidence for prophylactic treatment of children with cardiac medications is limited."1.42Absence of Cardiac Benefit with Early Combination ACE Inhibitor and Beta Blocker Treatment in mdx Mice. ( Blain, A; Blamire, AM; Greally, E; Laval, SH; MacGowan, GA; Straub, VW, 2015)
"Metoprolol was given orally (2."1.36Intolerance to ß-blockade in a mouse model of δ-sarcoglycan-deficient muscular dystrophy cardiomyopathy. ( Bauer, R; Blain, A; Bushby, K; Greally, E; Laval, S; Lochmüller, H; MacGowan, GA; Straub, V, 2010)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (75.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
Razzoli, M1
Lindsay, A1
Law, ML1
Chamberlain, CM1
Southern, WM1
Berg, M1
Osborn, J1
Engeland, WC1
Metzger, JM1
Ervasti, JM1
Bartolomucci, A1
Dittrich, S1
Graf, E1
Trollmann, R1
Neudorf, U1
Schara, U1
Heilmann, A1
von der Hagen, M1
Stiller, B1
Kirschner, J1
Pozza, RD1
Müller-Felber, W1
Weiss, K1
von Au, K1
Khalil, M1
Motz, R1
Korenke, C1
Lange, M1
Wilichowski, E1
Pattathu, J1
Ebinger, F1
Wiechmann, N1
Schröder, R1
Blain, A2
Greally, E2
Laval, SH1
Blamire, AM1
MacGowan, GA2
Straub, VW1
Bauer, R1
Bushby, K1
Lochmüller, H1
Laval, S1
Straub, V1

Trials

1 trial available for metoprolol and Muscular Dystrophy, Duchenne

ArticleYear
Effect and safety of treatment with ACE-inhibitor Enalapril and β-blocker metoprolol on the onset of left ventricular dysfunction in Duchenne muscular dystrophy - a randomized, double-blind, placebo-controlled trial.
    Orphanet journal of rare diseases, 2019, 05-10, Volume: 14, Issue:1

    Topics: Adolescent; Adrenergic beta-1 Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardio

2019

Other Studies

3 other studies available for metoprolol and Muscular Dystrophy, Duchenne

ArticleYear
Social stress is lethal in the mdx model of Duchenne muscular dystrophy.
    EBioMedicine, 2020, Volume: 55

    Topics: Adrenergic beta-Antagonists; Animals; Arterial Pressure; Disease Models, Animal; Dystrophin; Gait Di

2020
Absence of Cardiac Benefit with Early Combination ACE Inhibitor and Beta Blocker Treatment in mdx Mice.
    Journal of cardiovascular translational research, 2015, Volume: 8, Issue:3

    Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Calcium; Captopril;

2015
Intolerance to ß-blockade in a mouse model of δ-sarcoglycan-deficient muscular dystrophy cardiomyopathy.
    European journal of heart failure, 2010, Volume: 12, Issue:11

    Topics: Adrenergic beta-1 Receptor Agonists; Adrenergic beta-1 Receptor Antagonists; Animals; Disease Models

2010